Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications
Javier Fernández‐Ruíz, Marı́a A. Moro, José Martínez‐Orgado
Neurotherapeutics (2015) Vol. 12, Iss. 4, pp. 793-806
Open Access | Times Cited: 130

Showing 1-25 of 130 citing articles:

From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology
Alessia Ligresti, Luciano De Petrocellis, Vincenzo Di Marzo
Physiological Reviews (2016) Vol. 96, Iss. 4, pp. 1593-1659
Open Access | Times Cited: 418
CB 1 and CB 2 Receptor Pharmacology
A­llyn C. Howlett, Mary E. Abood
Advances in pharmacology (2017), pp. 169-206
Open Access | Times Cited: 296
The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases
Henry Lowe, Ngeh J. Toyang, Blair Steele, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9472-9472
Open Access | Times Cited: 206
Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target
Tommaso Cassano, Silvio Calcagnini, Lorenzo Pace, et al.
Frontiers in Neuroscience (2017) Vol. 11
Open Access | Times Cited: 173
Revisiting Traumatic Brain Injury: From Molecular Mechanisms to Therapeutic Interventions
Abbas Jarrahi, Molly Braun, Meenakshi Ahluwalia, et al.
Biomedicines (2020) Vol. 8, Iss. 10, pp. 389-389
Open Access | Times Cited: 168
Goods and Bads of the Endocannabinoid System as a Therapeutic Target: Lessons Learned after 30 Years
Mauro Maccarrone, Vincenzo Di Marzo, Jürg Gertsch, et al.
Pharmacological Reviews (2023) Vol. 75, Iss. 5, pp. 885-958
Open Access | Times Cited: 91
A comprehensive review of the multifaceted role of cannabinoid receptor type 2 in neurodegenerative and neuropsychiatric disorders
María S. García‐Gutiérrez, Abraham B. Torregrosa, Francisco Navarrete, et al.
Pharmacological Research (2025) Vol. 213, pp. 107657-107657
Open Access | Times Cited: 3
Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity
Xavier Nadal, Carmen del Río, S. Casano, et al.
British Journal of Pharmacology (2017) Vol. 174, Iss. 23, pp. 4263-4276
Open Access | Times Cited: 108
Polyunsaturated fatty acids and endocannabinoids in health and disease
Hércules Rezende Freitas, Alinny Rosendo Isaac, Renato Malcher‐Lopes, et al.
Nutritional Neuroscience (2017) Vol. 21, Iss. 10, pp. 695-714
Closed Access | Times Cited: 104
A Guide to Targeting the Endocannabinoid System in Drug Design
Adam Stasiulewicz, Katarzyna Znajdek, Monika Grudzień, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 8, pp. 2778-2778
Open Access | Times Cited: 104
Neuroprotection in Oxidative Stress-Related Neurodegenerative Diseases: Role of Endocannabinoid System Modulation
János Pálóczi, Zoltán V. Varga, George Hasko, et al.
Antioxidants and Redox Signaling (2017) Vol. 29, Iss. 1, pp. 75-108
Open Access | Times Cited: 100
Neuroprotective Phytochemicals in Experimental Ischemic Stroke: Mechanisms and Potential Clinical Applications
Hui Xu, Emily Wang, Feng Chen, et al.
Oxidative Medicine and Cellular Longevity (2021) Vol. 2021, Iss. 1
Open Access | Times Cited: 96
Cannabinoids in Medicine: A Multifaceted Exploration of Types, Therapeutic Applications, and Emerging Opportunities in Neurodegenerative Diseases and Cancer Therapy
Victor Voicu, Felix-Mircea Brehar, Corneliu Toader, et al.
Biomolecules (2023) Vol. 13, Iss. 9, pp. 1388-1388
Open Access | Times Cited: 28
The Effects of Cannabinoids on Ischemic Stroke-Associated Neuroinflammation: A Systematic Review
Eman A. Alraddadi, Faisal F. Aljuhani, Ghadah Y. Alsamiri, et al.
Journal of Neuroimmune Pharmacology (2025) Vol. 20, Iss. 1
Open Access | Times Cited: 1
Cannabis: A Treasure Trove or Pandora's Box?
Katalin Solymosi, Attila Köfalvi
Mini-Reviews in Medicinal Chemistry (2016) Vol. 17, Iss. 13
Open Access | Times Cited: 85
Could the Combination of Two Non-Psychotropic Cannabinoids Counteract Neuroinflammation? Effectiveness of Cannabidiol Associated with Cannabigerol
Santa Mammana, Eugenio Cavalli, Agnese Gugliandolo, et al.
Medicina (2019) Vol. 55, Iss. 11, pp. 747-747
Open Access | Times Cited: 74
TRP Channels as Novel Targets for Endogenous Ligands: Focus on Endocannabinoids and Nociceptive Signalling
Maksim V. Storozhuk, Alexander V. Zholos
Current Neuropharmacology (2017) Vol. 16, Iss. 2
Open Access | Times Cited: 68
Type-2 cannabinoid receptors in neurodegeneration
Tiziana Bisogno, Sergio Oddi, Alessandra Piccoli, et al.
Pharmacological Research (2016) Vol. 111, pp. 721-730
Closed Access | Times Cited: 66
Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update
Paula Morales, Laura Hernández‐Folgado, Pilar Goya, et al.
Expert Opinion on Therapeutic Patents (2016) Vol. 26, Iss. 7, pp. 843-856
Closed Access | Times Cited: 65
Potential Therapeutic Targets to Modulate the Endocannabinoid System in Alzheimer’s Disease
Hina Kanwal, Moris Sangineto, Martina Ciarnelli, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 7, pp. 4050-4050
Open Access | Times Cited: 7
Synaptopathic mechanisms of neurodegeneration and dementia: Insights from Huntington’s disease
Shiraz Tyebji, Anthony J. Hannan
Progress in Neurobiology (2017) Vol. 153, pp. 18-45
Closed Access | Times Cited: 58
Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor
Concepción García, María Gómez‐Cañas, Sonia Burgaz, et al.
Journal of Neuroinflammation (2018) Vol. 15, Iss. 1
Open Access | Times Cited: 58
Neuroprotective effects of the cannabigerol quinone derivative VCE-003.2 in SOD1G93A transgenic mice, an experimental model of amyotrophic lateral sclerosis
Carmen Rodríguez‐Cueto, Irene Santos‐García, Laura García‐Toscano, et al.
Biochemical Pharmacology (2018) Vol. 157, pp. 217-226
Closed Access | Times Cited: 52
Targeting glial cannabinoid CB2 receptors to delay the progression of the pathological phenotype in TDP‐43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis
Francisco Espejo‐Porras, Laura García‐Toscano, Carmen Rodríguez‐Cueto, et al.
British Journal of Pharmacology (2018) Vol. 176, Iss. 10, pp. 1585-1600
Open Access | Times Cited: 51
Potential of CBD Acting on Cannabinoid Receptors CB1 and CB2 in Ischemic Stroke
Iu Raïch, Jaume Lillo, Rafael Rivas‐Santisteban, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 12, pp. 6708-6708
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top